Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evoke Pharma (EVOK) Research & Development (2020 - 2025)

Historic Research & Development for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to $5320.0.

  • Evoke Pharma's Research & Development fell 5444.04% to $5320.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $56516.0, marking a year-over-year increase of 4535.26%. This contributed to the annual value of $16322.0 for FY2024, which is 9102.73% down from last year.
  • Per Evoke Pharma's latest filing, its Research & Development stood at $5320.0 for Q3 2025, which was down 5444.04% from $8413.0 recorded in Q2 2025.
  • In the past 5 years, Evoke Pharma's Research & Development ranged from a high of $277825.0 in Q1 2021 and a low of $4645.0 during Q1 2024
  • Over the past 5 years, Evoke Pharma's median Research & Development value was $41052.5 (recorded in 2022), while the average stood at $71625.7.
  • Its Research & Development has fluctuated over the past 5 years, first crashed by 9662.36% in 2021, then surged by 82105.49% in 2025.
  • Quarter analysis of 5 years shows Evoke Pharma's Research & Development stood at $35723.0 in 2021, then dropped by 23.84% to $27207.0 in 2022, then dropped by 17.08% to $22560.0 in 2023, then crashed by 48.24% to $11677.0 in 2024, then tumbled by 54.44% to $5320.0 in 2025.
  • Its last three reported values are $5320.0 in Q3 2025, $8413.0 for Q2 2025, and $42783.0 during Q1 2025.